Introduction
p16 is a key tumor-suppressor gene product that blocks the progression of the cell cycle by binding to either CDK4 or CDK6 and inhibiting the action of cyclin D (Serrano et al., 1993; Kamb et al., 1994; Nobori et al., 1994; Ortega et al., 2002) . The p16 gene has been found to be homozygously deleted, mutated or transcriptionally inhibited by methylation in a large number of different human tumor types, including sporadic melanoma (Kamb et al., 1994; Nobori et al., 1994; Ruas and Peters, 1998; Ortega et al., 2002) . Of note, p16 has also been found to be linked to familial melanoma, and is considered the most important melanoma susceptibility gene (Hussussian et al., 1994; Nobori et al., 1994; Haluska and Hodi, 1998) . Compelling epidemiological and basic science data support a critical causal role of sunlight exposure in the development of melanoma (Brash, 1997) , suggesting a plausible role of p16 in the cellular response to UV-induced DNA damage. Indeed, p16 is involved in G2 cell cycle delay in response to low UV doses, and its expression increases in UV-treated epidermally derived cell lines and in human skin (Milligan et al., 1998; Pavey et al., 1999) . Interestingly, in human skin, this increase is potentiated by the amelanocyte-stimulating hormone (a-MSH) (Pavey and Gabrielli, 2002) . p16 is also involved in other cellular functions such as senescence and apoptosis. Indeed, ectopic expression of p16 induced p53-dependent programmed cell death (apoptosis) in different cancer cells (Sandig et al., 1997; Kataoka et al., 2000; Katsuda et al., 2002; Tamm et al., 2002) . However, the role of p16 in DNA damage-mediated apoptosis is yet to be defined.
In most cancers, defective apoptosis is associated with the unscheduled cellular growth, allowing neoplastic cells to survive beyond their normal lifespan, evade several cellular controls, promote angiogenesis and expand (Hanahan and Weinberg, 2000) . Therefore, it became clear that cellular resistance to the apoptotic signals constitutes a major step in the carcinogenesis process. Moreover, defects in apoptosis affect the therapeutic outcome, since most of the agents used in cancer treatment, such as cisplatin or ionizing radiation, utilize apoptotic pathways to induce cell death (Johnstone et al., 2002) . Accordingly, several genes involved in apoptosis were found mutated in a broad range of cancers. This includes the tumor-suppressor p53 gene that plays a capital role as master regulator of the apoptotic program, and the Bcl-2 family proteins that are central regulators of the intrinsic-mitochondrial pathway (Miyashita et al., 1994a, b; Amundson et al., 1998; Zornig et al., 2001) . This family of cell death proteins is known to comprise proapoptotic proteins such as Bax and Bak, and antiapoptotic proteins like Bcl 2 and Bcl-X L (Johnstone et al., 2002) . In fact, overexpression of Bcl2 or Bcl-X L occurs in about half of all cancers, rendering tumor cells resistant to most cytotoxic anticancer agents (Amundson et al., 2000) . Moreover, overexpression of Bcl-2 accelerated tumorigenesis in transgenic mice (Adams et al., 1999) . Bax and Bak were also found mutated, or their expression was reduced in many tumors (Lowe et al., 1993 (Lowe et al., , 1994 Zornig et al., 2001) . In addition, loss of p53 function, which has been found in a large proportion of cancers, correlates with multidrug resistance in many tumor types (Lowe et al., 1993 (Lowe et al., , 1994 Zornig et al., 2001) . This resistance represents a major problem in cancer therapy, and seems to be associated with alterations in apoptosis pathways. Therefore, there is growing evidence that apoptosis links cancer genetics to cancer therapy. Consequently, a deeper understanding of the molecular mechanisms that underlie apoptosis will certainly lead to a new class of targets and more rational therapeutics.
In the present report, we investigated the role of the tumor suppressor p16 protein in UV-and cisplatininduced apoptosis. We have used the well-characterized U2OS cells that do not express the p16 gene due to methylation in the exon 1a-promoter, and their isogenic derivatives EH1 and EH2 cell lines that express p16 under the control of the IPTG-inducible promoter (McConnell et al., 1999) , as well as the isogenic MEFs (p16À/À and p16 þ / þ ). The results presented herein show that the p16 tumor-suppressor gene is a modulator of DNA damage-dependent apoptosis in both human and mouse cells.
Results

p16 expression decreases UV-dependent apoptosis in human U2OS cells
To elucidate the role of p16 in DNA damage-induced apoptosis, we performed flow cytometric analysis to determine the percentage of UV-dependent cell death in U2OS cells and their isogenic counterparts EH1 and EH2 cell strains, which contain p16 under the control of the IPTG inducible promoter. Importantly, in the absence of IPTG, EH1 and EH2 cell lines express a low basal level of p16, comparable to the low amount detected in early-passage human diploid fibroblasts, without exerting any measurable effect on cellular growth (McConnell et al., 1999) (data not shown). Each cell line was split into two subpopulations: one was sham-treated, while the other one was challenged with a UV fluence of 30 J/m 2 . Irradiated and nonirradiated cells were reincubated for different periods of time (0-72 h). The sub-G1 population corresponds to dead cells, the majority of which detached from the plate and showed shrinkage and membrane blebbing, characteristic of apoptotic cells (Wyllie et al., 1980) . Only a minor fraction of the nonirradiated U2OS cells underwent apoptosis (4% after 72 h of incubation), but when these cells were UV-irradiated, the proportion of apoptotic cells reached 58% (Figures 1a, b) . These results parallel what has been previously reported (Allan and Fried, 1999) . On the other hand, the p16-proficient EH1 and EH2 cells exhibited resistance to UV irradiation. At 72 h following UV treatment, only 21% of EH1 cells underwent apoptosis (Figures 1a, b) . This indicates that the proportion of UV-induced apoptotic cells is three times lower in EH1 than in U2OS. Similar results were obtained with the EH2 cell line (Figures 1a, b) .
The role of p16 in UV-induced apoptosis was also analysed using fluorescent annexin V, which identifies apoptotic cells by binding to phosphatidylserine when exposed on the outer leaflet of the plasma membrane. Cells were treated as described above, and were stained using alexa fluor 488 annexin V. Figure 1c shows that UV-dependent apoptosis is higher in U2OS than in EH1 cells. At 48 h subsequent UV treatment, not more than 10% of EH1 cells underwent apoptosis, whereas 30% of U2OS cells died through the apoptotic pathway ( Figure 1c) . Together, these results suggest a role for p16 in protecting the osteosarcoma U2OS cell line from UV-induced apoptosis.
To check whether this effect is due to p16-mediated G1-arrest, which in turn can protect cells from UVmediated apoptosis, U2OS cells were synchronized in the G1/S border and then split into two subpopulations before being UV-challenged with a fluence of 30 J/m 2 . One population was kept arrested with aphidicolin and the other one was allowed to reenter the cell cycle. Both populations were reincubated for 72 h, and then apoptosis was assessed by flow cytometry. About 65% of cells underwent apoptosis in both G1-arrested as well as nonarrested cells (data not shown), indicating that G1 arrest did not protect the osteosarcoma cell line U2OS against UV-mediated apoptosis.
p16 negatively controls UV-induced apoptosis in mouse cells
To confirm that p16 is an inhibitor of UV-induced apoptosis and to prove that this role is a common mechanism rather than a cell type-specific event, we investigated the apoptotic response of p16-compromised MEFs (Sharpless et al., 2001) and their normal isogenic counterparts. Both cell lines were split into two subpopulations and treated as described above for human cells. The nonirradiated p16À/À cells showed a very low percentage of cell death (6% after 72 h of incubation), but when these cells were challenged with a UV fluence of 30 J/m 2 , a large proportion of cells detached from the monolayer. After 72 h of incubation, 45% of cells became apoptotic (Figures 2a, b) . On the other hand, UV irradiation exerted only a slight effect on the p16 þ / þ cells. Only 1 and 10% of p16 þ / þ cells underwent apoptosis in the nonirradiated and UV-treated cells, respectively (Figures 2a, b) . This indicated that the proportion of UV-induced apoptotic cells is more than four times lower in p16 þ / þ than in p16-compromised MEFs, which confirmed what has been found in human cells. It is noteworthy that similar results were obtained when apoptosis was analysed using the DNA-laddering technique (data not shown). Together, these results show that p16 negatively controls UV-induced apoptosis in mammalian cells. 
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INK4a in DNA damage-induced apoptosis MA Al-Mohanna et al p16-dependent inhibition of UV-induced apoptosis correlates with downregulation of Bax p53 is a principal regulator of DNA damage-induced apoptosis. It can initiate apoptosis by transcriptionally activating proapoptotic Bcl-2 family members such as Bax, and repressing antiapoptotic Bcl-2 proteins like Bcl-2 (Selvakumaran et al., 1994; Reed, 1995) . To further understand the mechanism(s) whereby p16 mediates resistance to UV-induced apoptosis, we assessed the level of Bax and Bcl-2 in U2OS and EH1 cells after being UV-treated with a fluence of 10 J/m 2 . Figure 3 shows that, in both cell lines, p53 is induced in response to UV light, with the maximum level reached 4 h after the treatment. In U2OS cells, which exhibited a high proportion of UV-induced apoptosis, the level of the antiapoptotic protein Bcl-2 decreased over time, with the minimum level reached 24 h after the treatment. On the other hand, the levels of Bax and PCNA (used as internal control) did not show significant change ( Figure 3 ). However, the low proportion of UV-induced apoptosis observed in the EH1 cells was associated with downregulation of the Bax protein ( Figure 3 , compare time 0 with time 24 h), while the levels of Bcl-2 and PCNA remained constant ( Figure 3 ). Similar results were obtained when these cells were treated with a UV fluence of 30 J/m 2 (data not shown). These results suggest that p16 negatively controls UV-induced cell death through Bax downregulation and that in the absence of p16 a reduction in Bcl-2 level mediates apoptosis in response to photolesions.
p16 induces cisplatin-mediated apoptosis in EH1 cells
Cisplatin is a potent chemotherapeutic agent used to treat a wide range of human malignancies, for example, neuroblastoma, melanoma and osteosarcoma. The cytotoxicity of this anticancer drug is mediated principally through the apoptotic pathways (Gonzalez et al., 2001) . Thereby, we wanted to investigate the role of p16 in the cisplatin-induced apoptosis in both human and mouse cells. For this, both human cell lines U2OS and EH1 were split into two subpopulations: one was cisplatin-treated and the second was used as nontreated control. Subsequently, cells were reincubated for different periods of time (0-72 h). As expected, the nontreated cells did not undergo apoptosis over the 72 h of incubation (Figures 4a, b) . Cisplatin treatment of U2OS cells for 72 h yielded a very low fraction of apoptotic cells. Indeed, only about 12% of the p16-defective U2OS cells underwent apoptosis, showing the resistance of this cell line to cisplatin (Figures 4a, b) . Increasing the treatment time to 96 h did not enhance the proportion of apoptotic cells (data not shown). On the other hand, a great proportion of cisplatintreated EH1 cells detached from the plate and underwent apoptosis. 72 h of treatment resulted in 38% of apoptotic cells. It is noteworthy that EH1 cells started undergoing apoptosis only when they reached G2/M phase, after 48 h of cisplatin treatment (Figure 4) . When apoptosis was analysed by annexin V staining, similar results were obtained. Cisplatin treatment for 3 days led to a higher proportion of apoptosis in EH1 cells than in U2OS cells (Figure 4c ). These results show the ability of the p16 tumor-suppressor gene in sensitizing the osteosarcoma U2OS cell line to cell death induced by cisplatin.
Bcl-2 is downregulated in cisplatin-treated EH1 cells
To elucidate the molecular mechanism that underlies the resistance/sensitivity to cisplatin-induced apoptosis of U2OS and EH1 cell lines, the levels of Bax and Bcl-2 were assessed in these cells treated with the anticancer drug. Figure 5 shows that cisplatin treatment led to p53 upregulation in both cell lines, with the maximum level reached after 48 h of Figure 2 UV-dependent apoptotic response of p16À/À and p16 þ / þ MEFs. Cell treatment and the figure legends are as in Figure 1 Figure 3 Effect of UV light on Bax, Bcl-2 and p53 protein levels in U2OS and EH1 strains. U2OS and EH1 cells were UV-treated with 10 J/m 2 , reincubated and harvested after the indicated time periods for protein purification. Proteins (30 mg) were used for Western blot analysis using the appropriate antibody, as indicated
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INK4a in DNA damage-induced apoptosis MA Al-Mohanna et al treatment. For the Bcl-2/Bax proteins, while the level of the proapoptosis Bax protein remained constant throughout the whole period of treatment, the Bcl-2 levels decreased over time in both cell lines ( Figure 5 ). However, after 72 h of cisplatin-treatment, the downregulation of Bcl-2 is more pronounced in EH1, which parallels the higher apoptosis level observed in this cell line as compared to the p16-compromised U2OS. Together, these results indicate that p16 induces cisplatin apoptosis in the osteosarcoma cell line by promoting downregulation of the antiapoptosis Bcl-2 protein. Cisplatin-induced apoptosis is cell cycle-dependent in human EH1 cells Figure 4a showed that the treatment of the human EH1 cells with cisplatin induced apoptosis only when a large proportion of these cells reached the G2/M phase of the cell cycle. To test whether cisplatin induces apoptosis in these cells only when they are at the postreplicative stages of the cell cycle, EH1 cells were treated with this drug after being synchronized in G1 with aphidicolin, and were kept arrested in the same phase during the whole period of treatment with the chemotherapeutic drug. Figure 6 shows that after 72 h of cisplatin treatment, only a very small proportion of G1-arrested cells underwent apoptosis. In fact, G1-arrested EH1 cells were as sensitive to cisplatin as the proliferating U2OS cells. Similar results were obtained when these cells were starved, cisplatin treated and then reincubated in the same conditions, to keep them arrested in the G0/ G1 phase (data not shown). These results indicate that p16 does not sensitize U2OS cells to cisplatin when these cells are arrested in the G0/G1 phase.
p16 is required for cisplatin-induced apoptosis in MEFs
Next, we sought to elucidate the effect of cisplatin on MEF cells. p16À/À and p16 þ / þ cells were treated as described for human cells. For normal cells, cisplatin treatment for 3 days resulted in 40% apoptotic cells, while no more than 1% of the nontreated cells underwent apoptosis in the same period of time. This indicated that cisplatin enhanced apoptosis 40-fold in these cells (Figure 7) . Importantly, this figure also shows that the p16 þ / þ cells started undergoing apoptosis during the first 24 h of cisplatin treatment, which did not cause cellular accumulation in the G/2M phase of the cell cycle, unlike what has been observed in human cells. On the other hand, p16À/À exhibited a relatively high proportion of cell death before cisplatin treatment (7% at time 0) (Figure 7 ). Figure 7b shows that similar proportions of apoptotic cells were obtained in cisplatintreated and nontreated p16À/À MEFs. After 72 h of incubation, about 26% of cells underwent apoptosis in both populations (Figure 7b ). This showed that in p16-defective MEFs, cisplatin did not enhance apoptosis.
Comparing the cisplatin effect on p16 þ / þ and p16À/ À, it is clear that the presence of p16 reduces spontaneous cell death to some extent, and then sensitizes cells to cisplatin-induced apoptosis (Figure 7 ). This corroborates the results obtained in human cells, and indicates that p16 positively controls cisplatinmediated apoptosis in mammalian cells.
Discussion
Cells respond to DNA damage by triggering cell cycle arrest, and in some circumstances induce apoptosis, a genetically controlled cell death pathway. In the present report, we show that, in addition to its role as cell cycle Figure 4 Continued Figure 5 Effect of cisplatin on Bax, Bcl-2 and p53 protein levels in U2OS and EH1 strains. U2OS and EH1 cells were treated with cisplatin, reincubated and harvested after the indicated time periods for protein purification. Proteins (30 mg) weres used for Western blot analysis using the appropriate antibody, as indicated checkpoint gene, p16 is also a modulator of DNA damage-induced apoptosis in mammalian cells.
p16 is an inhibitor of UV-induced apoptosis
Using flow cytometric analysis, we show here that p16-compromised cells, osteosarcoma U2OS cell line as well as p16À/À MEFs are sensitive to apoptosis, following treatment with ultraviolet light. On the other hand, only a small proportion of the p16-proficient EH1/EH2 and MEF p16 þ / þ cells underwent UV-induced apoptosis, showing that the tumor suppressor p16 gene protects cells against UV damage-mediating apoptosis in both human and mouse cells. Importantly, the UV-mediated apoptosis observed in U2OS coincided with a decrease in the level of the antiapoptosis Bcl-2 protein, with no effect on the level of the apoptosis agonist Bax protein.
However, in EH1 cells the reduction in UV-induced apoptosis was associated with downregulation of Bax expression, whereas the level of the Bcl-2 protein remained constant. This suggests that p16 negatively controls UV-induced apoptosis by downregulating the level of the apoptosis agonist Bax protein. However, in the absence of p16, UV damage triggers apoptosis by downregulating the apoptosis antagonist Bcl-2. Therefore, p16 is controlling UV-dependent apoptosis through the intrinsic-mitochondrial cell death pathway, which is under the control of the p53 tumor-suppressor protein.
In line with these findings, it has been previously shown that ectopic expression of p21 delays p53-dependent UV-induced apoptosis in U2OS cells (Allan and Fried, 1999) , indicating that p21 overexpression and p16 expression have a similar antiapoptotic effect in the p16-compromised U2OS cells. Interestingly, we have found that UV-dependent induction of p21 is under the control of the p16 gene (data not shown). Together, these results indicate that the effect of p16 on p53-dependent UV-induced apoptosis may be p21-dependent. Although the role of p21 in apoptosis is still not well defined, there are reports that point to an apoptosis-inhibitory effect of p21 (Poluha et al., 1996; Polyak et al., 1996; Gorospe et al., 1997; Bissonnette and Hunting, 1998; Canman and Kastan, 1998; Allan and Fried, 1999) . Since both proteins are regulators of the cell cycle and essential for G1 arrest in response to DNA damage, it was important to see whether p16 protects cells from undergoing apoptosis in response to UV radiation by arresting them in G1. Importantly, G1-arrested U2OS cells with aphidicolin were as sensitive to UV-induced apoptosis as the nonarrested cells, indicating that p16 does not protect these cells against apoptosis by allowing a G1 arrest following UV damage. Thus, how does p16 protect cells against UVmediated apoptosis? While DNA damage induced by UV light is known to be responsible for UV-induced genotoxicity, its role in triggering apoptosis is still unclear. In fact, there is compelling evidence that UV-induced apoptosis is triggered by the nonrepaired photolesions, especially those that block transcription (Ljungman and Zhang, 1996; Bissonnette and Hunting, 1998; McKay et al., 1998; Dunkern et al., 2001 ). This shows a direct link between apoptosis and DNA repair of the transcribed strands. Therefore, it is possible that p16 negatively controls UV-induced apoptosis by allowing DNA repair of these mutagenic lesions. This suggests that p16-defective cells should be deficient in repairing UV damage. Indeed, dysplastic nevus syndrome (DNS) cells that bear a deleted p16 gene were found to be more sensitive than normal Figure 6 Cisplatin does not induce apoptosis in G1-arrested EH1 cells. Synchronized cells at the G1/S border with aphidicolin (a) or IPTG-induced p16 (b) were either sham-treated or challenged with cisplatin for the indicated times. Cells were then reincubated in the presence of aphidicolin to keep them arrested. Apoptosis was then analysed by flow cytometry cells to UVC (Abrahams et al., 1998) . Moreover, hypermutability of UV-treated plasmids has been observed in p16-compromised dysplastic nevus/familial melanoma cell lines, which also suggested a defect in repairing UV-induced DNA damage that could be due to mutated p16 gene (Moriwaki et al., 1997) . Together, these results reveal that p16 could constitute a link between DNA repair capacity of UV damage and apoptosis. As a case in point, it has been recently shown that UV-induced DNA damage induces apoptosis in nucleotide excision repair-deficient Chinese hamster cells via Bcl-2 decline, which parallels what has been shown here for U2OS. Interestingly, overexpression of Bcl-2 protected these cells against apoptosis, indicating that Bcl-2 decline is causally involved in UV-mediated apoptosis (Dunkern et al., 2001 ). This Figure 7 Cisplatin-dependent apoptotic response of the p16À/À and p16 þ / þ MEFs. Cell treatment and the figure legends are as in Figure 4 Role of p16
INK4a in DNA damage-induced apoptosis MA Al-Mohanna et al shows that in response to UV damage there is a relationship between DNA repair capacity and the Bcl-2 expression. Therefore, it is possible that p16 is protecting cells from undergoing apoptosis in response to UV damage, by allowing efficient repair of photolesions and modulating the levels of the Bcl-2/Bax proteins.
p16 sensitizes the osteosarcoma U2OS cells to cisplatininduced apoptosis
Cisplatin is widely used for the treatment of different types of cancers including osteosarcoma, bladder and testicular cancers. Genomic DNA is the major target of cisplatin, which induces its cytotoxicity by activating programmed cell death (Gonzalez et al., 2001) . Although cisplatin initiates apoptosis through pathways modulated by p53, this tumor-suppressor gene is not essential for cisplatin-induced apoptosis (Zamble et al., 1998) . In this investigation, we present evidence that cisplatin-mediated cell death is p16-dependent in mammalian cells. Indeed, cisplatin treatment of the osteosarcoma U2OS cell line induced apoptosis in only about 10% of cells, while more than 40% of the EH1 cells underwent apoptosis under the same conditions. Similarly, p16 sensitized MEFs to cisplatin-induced apoptosis. Interestingly, while in p16 þ / þ MEFs apoptotic cells were detected during the first 24 h of cisplatin treatment, the p16-dependent apoptosis was initiated in EH1 cells only when they reached the G2/M phase of the cell cycle, after 48 h of treatment. This suggested that these cells initiate apoptosis only in the postreplicative stages. This result corroborates what has been previously reported in murine leukemia L1210 cells that also accumulated in G2 following cisplatin treatment. The duration of the G2 block was proportional to the concentration of the drug (Sorenson and Eastman, 1988b) . The discrepancy observed between mouse and human cells could be due to the fact that the mechanism of cisplatin-induced apoptosis in human cells is different from that in MEFs. To assess the importance of the accumulation of cisplatin-treated cells in G2/M for the initiation of apoptosis, EH1 cells were synchronized in G1 phase, and were kept arrested after being challenged with the drug. Interestingly, in these conditions only a small proportion of EH1 cells underwent apoptosis ( Figure 6 ). A similar result was obtained when the same cells were treated with the drug in starved nonreplicating condition (data not shown), indicating that nonproliferating p16-proficient cells are resistant to cisplatin. Similarly, cisplatin triggered apoptosis in immature rat thymocytes only when they were proliferating, but not at quiescence (Evans et al., 1994) . Together, these results indicate that cisplatin triggers apoptosis only in proliferating cells, which is not the case for several other chemotherapeutic drugs (Evans et al., 1994) . This explains the wide use of cisplatin in the treatment of different tumor cells, which are characterized by noncontrolled proliferation. Nevertheless, there is compelling evidence from different lines of investigation to suggest that cisplatin-dependent apoptosis is not the result of inhibition of DNA synthesis. In fact, DNA repair-deficient cells die at concentrations of cisplatin that do not inhibit DNA replication. In addition, cells proficient in DNA repair survive at high concentrations of cisplatin, which is able to inhibit DNA synthesis (Sorenson and Eastman, 1988a) . These results showed that replicating cisplatin-damaged DNA is not a prerequisite for triggering apoptosis. Importantly, p16-dependent cisplatin-induced apoptosis was associated with downregulation of the antiapoptosis Bcl-2 protein. Similarly, it has been shown in a recent report that downregulation of Bcl-2 is associated with p16-mediated apoptosis in non-small-cell lung cancer cells (Kataoka et al., 2000) . This clearly shows the ability of p16 in regulating the level of the proapoptosis Bcl-2 protein.
Together, these results indicate that p16 is involved in cisplatin-induced apoptosis through the regulation of Bcl-2.
The present data, showing that p16 can sensitize p16-negative cells to cisplatin, may have implications in cancer treatment based on the introduction of p16 combined with chemotherapy. However, it has been shown in previous reports that the introduction of p16 in bladder cancer cells and melanoma cells conferred rather increased chemoresistance to cisplatin (Stone et al., 1996; Grim et al., 1997) . But, in these experiments p16 was highly expressed and promoted G0-G1 arrest to the transfected cells. Importantly, here we provide evidence that G1-arrested p16-proficient EH1 cells are as resistant to cisplatin as p16-compromised U2OS cells, indicating that, in contrast to UV light, cellular arrest at the G1 phase protects cells against cisplatin-induced apoptosis even in the presence of p16. This shows that to sensitize p16-deficient cells to cisplatin, p16 should be introduced and expressed only at low levels, which will complement p16 deficiencies without causing cell cycle arrest at the G1 phase. Thereby, combining gene replacement with chemotherapy may lead to a more efficient treatment of some chemoresistant tumors, based on their genetic background.
Materials and methods
Cell lines
The three human cell lines used were U2OS, human osteosarcoma cell line, which does not express endogenous p16 due to hypermethylation, EH1 and EH2, derived from U2OS, which express p16 under the control of the IPTGinducible promoter (McConnell et al., 1999) . (The three cell lines were a generous gift from Dr G Peters). The mouse embryo fibroblasts used were p16 (WT) and their p16-specific knockout counterpart (Sharpless et al., 2001) . (MEF cell lines were a generous gift from Dr RA DePinho.)
UV irradiation and cisplatin treatment
Cells were grown to confluence in Dulbecco's modified Eagle medium (DMEM) with supplements. The medium was removed and the monolayers in dishes were covered with phosphate-buffered saline (PBS) and exposed to a germicidal UV lamp (254 nm) at a fixed distance for different periods of time. The UV dosimetry was performed using an ultraviolet meter (Spectronics Corporation, NY, USA). Cisplatin (DBL, Warwick, UK) was used at a final concentration of 6 mg/ml.
Synchronization
Cells were synchronized at the G1/S boundary using aphidicolin, as previously described (Al-Mohanna et al., 2001) .
Apoptosis analysis by flow cytometery
Cells were challenged either with UVC at a dose of 30 J/m 2 or with cisplatin, whereupon the monolayers were incubated in DMEM medium with supplements. Detached and adherent cells were then harvested at various times (0-72 h), centrifuged and resuspended in 1 ml PBS. Cells were then stained either by propidium iodide (PI) or by Alexa Fluor 488 annexin V. For PI staining, cells were fixed by dropwise addition of 3 ml of 100% methanol. The fixed cells were then centrifuged, resuspended in 50 ml of RNase (1 mg/ml) and incubated for 30 min at room temperature, followed by the addition of 1 ml of 0.1 mg/ml of PI. Cells were analysed for DNA content by flow cytometry (Becton Dickinson, San Jose, CA, USA). The percentage of cells in various cell cycle phases was determined by using Cell Quest Pro software (Becton Dickinson). Annexin V staining was performed using Vybrant Apoptosis Assay kit #2 (Molecular Probe) following the manufacturer's recommendations. Annexin V-stained cells were analysed by flow cytometry, measuring the fluorescence emission at 530 and 4575 nm.
Cellular lysate preparation
Treated cells with UV light (10 J/m 2 ) or cisplatin were reincubated for various times. Cells were next washed and scraped in lysis buffer (150 mm NaCl, 1% Triton X-100, 50 mm Tris-HCl (pH 7.5)), supplemented with 40 mg/ml aprotinin, 20 mg/ml leupeptin and 5 mg/ml pepstatin. Lysates were homogenized and then centrifuged at 14 000 r.p.m. in an Eppendorf microcentrifuge tube for 20 min. The supernatant was removed, aliquoted and stored at À801C.
Immunoblotting SDS-PAGE was performed using 12% separating minigels. Equal amounts of protein from different samples were placed in boiling water for 10 min in the presence of the SDS gel sample buffer (0.5 m Tris pH 6.8, 10% glycerol, 10% SDS, 5% 2-mercaptoethanol, 1% bromophenol) and electrophoresed for 2 h at 125 V. After transfer onto polyvinylidene difluoride membrane (PVDF), the membrane was first blocked with 5% powdered skimmed milk in PBST (138 mm NaCl, 2.7 mm KCl pH 7.4, 0.1% Tween) for 2 h, and then incubated with the appropriate first antibody overnight. Visualization of the second antibody was performed using a chemiluminescence detection procedure, according to the manufacturer's protocol (Amersham Pharmacia Biotech).
Monoclonal antibodies directed against p53 (DO-I), Bcl-2 (100), Bax (B-9) and PCNA (PC10) were purchased from Santa Cruz (USA).
